NRXP:NASDAQ, NRx Pharmaceuticals, Inc.

Why NRXP stock fell on November 20

NRx Pharmaceuticals, Inc. fell 15.7% on Friday, November 20, 2026, on 1,472,778 shares. No headline about NRXP came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

NRXP stock overview

NRx Pharmaceuticals, Inc. (NRXP:NASDAQ) closed at $2.15 on November 20, 2026, down 15.69% on the day. The stock trades 57.5% below its 52-week high of $5.06 and 32.7% above its 52-week low of $1.62. Over the past year, it lost 4.0%. NRx Pharmaceuticals, Inc. is part of the Health Care sector.

Key figures

Price
$2.15
Day change
-15.69%
Volume
1,472,778
Average volume
1,059,770
Market cap
95M+
52-week range
$1.62 – $5.06
50-day average
$2.75
200-day average
$2.98

Price action over the past year

In 252 trading sessions since November 20, 2025, NRXP closed higher on 120 days (48%). Its best day was May 26, 2026 (+33.85%) and its worst was November 20, 2026 (-15.69%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

NRXP news

About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Similar stocks

Find more stocks like NRXP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.